We report here a patient with advanced oral cancer in which concurrent chemoradiotherapy with TS-1 was performed. The patient was an 82-year-old male who had a 41 x 22 mm tumor mass around the left lower gingiva, whose X-ray showed a bone resorption image reaching the mandibular canal. We carried out concurrent chemoradiotherapy with TS-1. After 4 weeks, severe side effects, i.e., stomatitis and diarrhea, force us to discontinue the treatment. However, the tumor had begun to shrink from the 2nd week of treatment, and had clinically disappeared by the 8th week. The histopathological examination also indicated a complete response (CR). Thus, this treatment was very effective and may be useful for advanced cases.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Surgical and Long-term Outcomes of Combined Organ Resection for Esophageal Cancer Invading Adjacent Organs: Experience of 90 Consecutive Cases.
J Thorac Cardiovasc Surg
January 2025
Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Suita City, Osaka, 565-0871, Japan.
Objective: To evaluate the feasibility of and long-term survival with combined organ resection for esophageal cancer (EC).
Background: The optimal treatment strategy for EC that is invading adjacent organs is not established.
Methods: Ninety patients with EC invading adjacent organs who underwent combined organ resection after induction treatments during 2003-2023 in our institute were eligible for the study.
The value of magnetic resonance imaging in predicting vesicovaginal fistula in cervical cancer with bladder invasion treated with definitive chemoradiotherapy.
Gynecol Oncol
January 2025
Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. Electronic address:
Objectives: To assess the predictive value of magnetic resonance imaging for vesicovaginal fistula development in cervical cancer patients with bladder invasion treated with definitive chemoradiotherapy.
Methods: A retrospective review was conducted of the medical records of 43 cervical cancer patients with bladder invasion between 1999 and 2015. Bladder invasion was confirmed through magnetic resonance imaging (scores ≥3) or cystoscopic findings, with or without biopsy.
"Evaluating Current Diagnostic and Treatment Challenges in Colorectal Cancer: Strategies for improving care and outcomes in Georgia".
Cancer Treat Res Commun
January 2025
Caucasus Medical Centre, Tbilisi, Georgia; Ilia State University- School of Medicine. Tbilisi, Georgia. Electronic address:
Purpose: An initial analysis of population-based cancer survival data from Georgia revealed lower CRC survival rates compared to high-income countries. We conducted the study to address this issue and propose strategies for enhancing CRC care.
Patients And Methods: We analyzed CRC statistics, reviewed screening programs, and examined published CRC research in Georgia.
Significance of adding chemotherapy to radiotherapy in the treatment of T2N0 glottic cancer.
Jpn J Clin Oncol
January 2025
Department of Otorhinolaryngology, Head and Neck Surgery, Yokohama City University, School of Medicine, Yokohama, Japan.
The prognosis for T2N0 glottic squamous cell carcinoma (SCC) is generally favorable, with a 5-year overall survival rate of 79%-96% achieved with radiotherapy (RT), the standard nonsurgical treatment for this condition. However, the local control rate for T2N0 glottic SCC treated with RT remains suboptimal, with a 5-year local control rate of only 65%-80%. Local residual disease or recurrence following RT for T2N0 glottic SCC often leads to difficulties in laryngeal preservation.
View Article and Find Full Text PDFRandomized Evaluation of the PET-Adjusted IMRT for NSCLC Trial (REPAINT).
Int J Radiat Oncol Biol Phys
January 2025
Montefiore Einstein Comprehensive Cancer Center, Bronx, NY.
Background: Standard radiotherapy (RT) for locally advanced NSCLC (LA-NSCLC) employs a uniform dose of approximately 60 Gy. Recent trials demonstrated that radiotherapy dose escalation may not improve outcomes and may cause added toxicity. XXX previously performed a single-arm trial testing a personalized, risk-adapted, and de-intensified RT strategy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!